PADCEV™ (enfortumab vedotin) plus KEYTRUDA™ (pembrolizumab) significantly improves survival for certain patients with bladder cancer when given before and after surgery
Enfortumab vedotin plus pembrolizumab is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder cancer Results will be discussed with global health authorities for potential regulatory filings
Astellas Pharma recently announced positive topline results from the Ph